Novartis AG - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US66987V1098
121,00 € 0,00 (0,00%)
2026-06-04
AKTIENPREIS
SecurityDE:NOTA / Novartis AG - Depositary Receipt (Common Stock)
InstitutionBbr Partners, Llc
Latest Disclosed Ownership1,450 shares
Latest Disclosed Value $ 221,488
Bbr Partners, Llc reports 38.11% decrease in ownership of NOTA / Novartis AG - Depositary Receipt (Common Stock)

On May 12, 2026 - Bbr Partners, Llc filed a 13F-HR form disclosing ownership of 1,450 shares of Novartis AG - Depositary Receipt (Common Stock) (DE:NOTA) valued at $186,325 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 2,343 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of -38.11% during the quarter. The current value of the position is $175,450 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 1,450 -893 -38.11 221 -31.58 0.0124
2026-02-10 2025-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,343 0 0.00 323 7.67 0.0173
2025-11-07 2025-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,343 -222 -8.65 300 -3.23 0.0173
2025-08-14 2025-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 0 0.00 310 8.77 0.0193
2025-05-14 2025-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 0 0.00 286 14.46 0.0202
2025-02-07 2024-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 0 0.00 250 -15.59 0.0174
2024-11-13 2024-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 0 0.00 295 8.06 0.0225
2024-08-05 2024-06-30 13F Novartis A G Sponsored ADR COM 66987V109 2,565 -4,593 -64.17 273 -60.55 0.0224
2024-05-14 2024-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 7,158 2,959 70.47 692 63.59 0.0555
2024-02-13 2023-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 4,199 1,430 51.64 424 50.00 0.0433
2023-11-14 2023-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,769 0 0.00 282 1.08 0.0317
2023-08-08 2023-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,769 0 0.00 279 9.84 0.0309
2023-05-11 2023-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,769 204 7.95 255 9.48 0.0294
2023-02-13 2022-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 2,565 233 0.0262
2022-11-10 2022-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 0 -2,565 -100.00 0 -100.00
2022-08-12 2022-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 0 0.00 217 -3.56 0.0254
2022-05-16 2022-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 -708 -21.63 225 -21.33 0.0212
2022-02-08 2021-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 3,273 708 27.60 286 36.19 0.0336
2021-11-12 2021-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 0 0.00 210 -10.26 0.0174
2021-08-13 2021-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 2,565 -461 -15.23 234 -9.65 0.0185
2021-05-17 2021-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 3,026 -2 -0.07 259 -9.44 0.0213
2021-02-16 2020-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 3,028 0 0.00 286 8.75 0.0237
2020-11-12 2020-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 3,028 -6,128 -66.93 263 -67.12 0.0225
2020-08-11 2020-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 9,156 -5,985 -39.53 800 -35.90 0.1010
2020-05-14 2020-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 15,141 -2,265 -13.01 1,248 -24.27 0.1857
2020-02-14 2019-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 17,406 12,309 241.49 1,648 272.01 0.1804
2019-11-12 2019-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 5,097 171 3.47 443 -1.56 0.0675
2019-08-14 2019-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 4,926 576 13.24 450 7.66 0.0719
2019-05-10 2019-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 4,350 -10 -0.23 418 11.76 0.0543
2019-02-08 2018-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 4,360 10 0.23 374 -0.27 0.0492
2018-11-13 2018-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 4,350 0 0.00 375 13.98 0.0542
2018-08-14 2018-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 4,350 -224 -4.90 329 -11.08 0.0553
2018-05-09 2018-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 4,574 4,574 370 0.0662
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.